linjc16/ctgov huggingface dataset:
the Value of Immunohistochemical Expression of Moesin in Endometrial Hyperplasia and Endometrial Carcinoma

Study Overview
=================
Brief Summary
-----------------
Endometrial carcinoma (EC) is the most prevalent invasive carcinoma of the female genital tract in developed countries, while it ranks as the second most frequently occurring neoplasm of women in developing countries, after carcinoma of the cervix uteri. The vast majority of ECs occur in perimenopausal and postmenopausal women . ECs are classified into two distinct phenotypes; type I which represents more than 80% of all cases of ECs, it has a favorable prognosis. This type is linked to excess, unopposed hyper-estrogenic condition and it is almost always preceded by endometrial hyperplasia. On the contrary, type II endometrial carcinoma is less common than type I, representing less than 10% of all cases of ECs. Type II endometrial carcinomas are high grade, poorly differentiated and estrogen-independent tumors .

Official Title
-----------------
the Value of Immunohistochemical Expression of Moesin in Endometrial Hyperplasia and Endometrial Carcinoma

Conditions
-----------------
Endometrial Cancer and Endometrial Hyperplasia

Intervention / Treatment
-----------------
* Device: microscopic pathological evaluation


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Hysterectomy specimens diagnosed as endometrial hyperplasia and endometrial adenocarcinoma. All cases of endometrial biopsies obtained by curettage (D&C) diagnosed as endometrial hyperplasia. Cases of cyclical endometrium obtained from endometrial curettage or hysterectomy specimens done for pathological conditions other than hyperplastic or neoplastic endometrial lesions. Complete clinical data. Exclusion Criteria: Patients with a history of preoperative chemotherapy and /or radiotherapy. Biopsies with predominantly blood clots. Insufficient or tiny tissue biopsies.
Sexes Eligible for Study
-----------------
Female

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| endometrial carcinoma smples<br> | Device: microscopic pathological evaluation<br>* description of moesin expression between endometrial hyperplasia and endometrial carcinoma<br>|
| endometrial hyperplasia samples<br> | Device: microscopic pathological evaluation<br>* description of moesin expression between endometrial hyperplasia and endometrial carcinoma<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| The value of immunohistochemical expression of moesin in endometrial hyperplasia and endometrial carcinoma | To evaluate immunohistochemical expression of moesin in normal, hyperplasic and neoplastic endometrial tissues , correlate this expression with different clinicopathologic parameters of endometrial carcinoma and to evaluate the role of moesin as prognostic marker in progression from preinvasive lesions of the endometrium to endometrial carcinoma. | 1 year |
Swedish Adjustable Gastric Banding Observational Cohort Study

Study Overview
=================
Brief Summary
-----------------
Longitudinal prospective cohort study of patients treated consecutively by SAGB in a sample of centers representative of this activity in France. Verification by means of a screening log (exhaustive list of all bariatric procedures performed by participating surgeons between the beginning and end of the cohort inclusion period) requested from all centers. No comparator group. No randomization or blinding techniques

Detailed Description
-----------------
Longitudinal prospective cohort study of patients treated consecutively by SAGB in a sample of centers representative of this activity in France. The study is originated in collaboration with HAS in France and has a target of 500 patients treated with gastric banding because of morbid obesity.

Official Title
-----------------
Prospective National Cohort Study on Swedish Adjustable Gastric Band (SAGB) for Gastroplasty (Étude de Cohorte Nationale Prospective de l'Implant Annulaire Ajustable Pour Gastroplastie SAGB)

Conditions
-----------------
Obesity, Morbid

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: morbidly obese patients (BMI>35 with comorbidities or BMI>40 without comorbidities) in France selected for gastric banding based on standard local clinical practice Exclusion Criteria: lower BMI, contraindications based on local clinical assessment

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Patients treated with SAGB by solicited teams<br>Patients treated with SAGB by solicited teams. No selection criteria at cohort inclusion applied to the 500 (+50) first patients treated in order to ensure consecutive and exhaustive recruitment in the concerned centers over the inclusion period. | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Mean BMI Change | Mean change in BMI for valid subjects | 3 years follow-up | 
| Mean Excess Weight Change | Mean excess weight change in valid subjects. Excess weight is calculated as body weight minus ideal body weight, where ideal body weight is determined by the method of Lorentz (Ein neuer Konstitionsinde. Klin Wochenschr 1929; 8:348-51). | 3 years follow up |
Albumin Use in Burn Patients

Study Overview
=================
Brief Summary
-----------------
This is a study of why and how physicians use albumin during the first 72 hours after a burn injury.

Detailed Description
-----------------
While albumin has been a part of burn resuscitation for many years, its use remains varied and controversial. The purpose of this study is to describe the current practices of albumin administration during the first 72 hours after a burn injury. Participating sites will collect data on patients with at least a 20% Total Body Surface Area (TBSA) burn. Information will be recorded on type and extent of burn injury, basic demographic data, co-morbidities, outcomes and, for the first 72 hours post injury, if albumin was used and why, amount of resuscitation fluids and urine output, and use of vasopressors and diuretics. Each participating site will retrospectively review 20 charts of consecutive admissions with at least a 20% TBSA burn. In addition, each site will collect data prospectively on 20 more patients with 20% TBSA burns. Prospective data is requested in order to capture as close as possible to real time the reasons physicians choose to give albumin. No Protected Health Information (PHI) will be recorded. Data will be analyzed for patterns of albumin use and reasons for albumin administration.

Official Title
-----------------
Albumin Use in Burn Patients

Conditions
-----------------
Burns

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Burn Injury, with and without inhalation injury Exclusion Criteria: <20% Total Body Surface Area Burned Comfort care only for the burn injury
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Burns, Albumin, Fluid Resuscitation
PASCAL: Safety and Complications, Experience After 1301 Consecutive Cases

Study Overview
=================
Brief Summary
-----------------
To report the safety and incidence of adverse effects, during and after a successful photocoagulation for different pathologies using a Pattern Scan Laser (PASCAL) system and its modified settings

Official Title
-----------------
Pattern Scan Laser Photocoagulation: Safety and Complications, Experience After 1301 Consecutive Cases.

Conditions
-----------------
Bruch Rupture, Choroidal Detachment

Intervention / Treatment
-----------------
* Procedure: Panretinal Photocoagulation [Pattern Scan Laser (PASCAL) system]


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients treated with PASCAL system Exclusion Criteria: Uncompleted file. Loss of follow-up.

Ages Eligible for Study
-----------------
Minimum Age: 10 Years
Maximum Age: 90 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Procedure: Panretinal Photocoagulation [Pattern Scan Laser (PASCAL) system]|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Complication rates |  | during treatment and follow-up | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Panretinal photocoagulation, Bruch rupture, Choroidal detachment, complication rates
the Insulin Resistance in Recurrent Miscarriage IN RECURRENT ABORTION

Study Overview
=================
Brief Summary
-----------------
THE INSULIN RESISTANCE IN RECURRENT ABORTION

Detailed Description
-----------------
THE ROLE OF INSULIN RESISTANCE IN RECURRENT ABORTION

Official Title
-----------------
Insulin Resistance and Recurrent Abortion

Conditions
-----------------
Recurrent Abortion

Intervention / Treatment
-----------------
* Other: insulin resistance(fasting glucose/fasting insulin)


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Women in the child bearing period between 23-40 years. All patients are pregnant. The gestational age of both groups 6-13 weeks Exclusion Criteria: Patients with gestational diabetes and gestational impaired glucose tolerance. The patients who took medication that could affect glucose metabolism at the time of the study Patients with other causes of recurrent abortion as(thyroid dysfunction, uterine anomalies chromosomal abnormalities, antiphspholipid antibody syndrome, uterine anomalies and TORCH syndrome). Patients with PCOS. Obese patients(BMI>30)

Ages Eligible for Study
-----------------
Minimum Age: 23 Years
Maximum Age: 40 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| group A<br>cases with recurrent abortion with insulin resisance | Other: insulin resistance(fasting glucose/fasting insulin)<br>* insulin resistance(fasting glucose/fasting insulin )<br>|
| GROUP B<br>cases that are pregnant with no history of recurrent abortion with no insulin resistance | Other: insulin resistance(fasting glucose/fasting insulin)<br>* insulin resistance(fasting glucose/fasting insulin )<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| fasting blood glucose | Click here for more information about this study: the role of insulin resistance in recurrent abortion | 3 month | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| fasting Insulin |  | 3 month |
Perioperative Lung Ultrasonography for Fast-track Cardiac Surgery

Study Overview
=================
Brief Summary
-----------------
The investigators evaluate the usefulness of lung ultrasonography in the perioperative period for postoperative outcomes in children undergoing fast track cardiac surgery.

Detailed Description
-----------------
Some appropriate intervention such as recruitment maneuver, chest tube insertion, or diuretics will be applied depending on lung ultrasound findings.

Official Title
-----------------
The Effect of Perioperative Lung Ultrasonography on Postoperative Outcomes in Children Undergoing Fast-track Cardiac Surgery

Conditions
-----------------
Pulmonary Complication

Intervention / Treatment
-----------------
* Other: Treatment according to lung ultrasonography


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Children receiving fast track cardiac surgery protocol = or < 5 years old Children with acyanotic heart disease Exclusion Criteria: Previous history of lung resection surgery Preoperative chest x-ray abnormalities Postoperative cyanosis

Ages Eligible for Study
-----------------
Maximum Age: 5 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Prevention
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| No Intervention: Control group<br>No intervention is performed. Lung ultrasonography is performed within 4 hours after surgery for diagnostic purpose. | |
| Experimental: lung ultrasonography group<br>Lung ultrasonography is performed three times; after tracheal intubation, before surgery end, and within 4 hours after surgery. In this group, respiratory management is performed according to diagnosis. | Other: Treatment according to lung ultrasonography<br>* Appropriate treatment for atelectasis, pleural effusion, pulmonary edema, pneumothorax or pneumonia which are confirmed by lung ultrasonography<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Postoperative pulmonary complications | Pleural effusion, atelectasis, diaphragmatic dysfunction, pulmonary infection, embolism, respiratory failure, aspiration, pneumothorax, chylothorax, bronchospasm | Up to postoperative day 5 | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Duration of the use of inotropes | Duration of the use of inotropes | Up to postoperative day 5 | 
| Length of intensive care unit stay | Length of intensive care unit stay | up to postoperative day 5 | 
| Lung ultrasonography findings | Diagnostic lung ultrasonography | until 4 hours after surgery | 
| ABGA result | arterial blood gas analysis results | within 4 hours after extubation | 
| Duration of oxygen therapy |  | Up to postoperative day 5 |
SIS Evaluation of the MRI Defined Subthalamic Nucleus*

Study Overview
=================
Brief Summary
-----------------
Retrospective review of images used to target the STN during DBS procedure and ability of the Surgical Information Sciences (SIS) system to visualize the STN location.

Detailed Description
-----------------
The purpose of this study is to collect retrospective data to demonstrate the ability of the SIS system to visualize the MRI-defined STN in patients with Parkinson's Disease (PD) who have undergone deep brain stimulation (DBS) procedure targeting the STN.

Official Title
-----------------
Retrospective Multi-Site Re-Evaluation of the MRI Defined STN and Its Correlation to Motor Outcomes With Stimulation Treatment

Conditions
-----------------
Deep Brain Stimulation

Intervention / Treatment
-----------------
* Device: SIS System


Participation Criteria
=================
Eligibility Criteria
-----------------
Key Inclusion Criteria: Idiopathic PD Bilateral or unilateral STN-HFS for PD 40% improvement response to medications preoperatively Key Exclusion Criteria: Missing required MR/CT imaging data

Ages Eligible for Study
-----------------
Minimum Age: 50 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Device: SIS System|Software technology for visualization of anatomical structures in the brain|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Percent of STN Visualization Success | Measure the proportion of images successfully processed for visualization of the STN over total number of image sets | Day 1 | 
| Incidence of DBS Lead Location in Proximity to STN | Determine incidence in which the location of the DBS lead is in or outside the STN | Day 1 | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Rate of Correlation of Predicted Outcome to Monopolar Review Outcome | Rate of blinded predicted outcome compared to monopolar review outcomes | 1 Month | 
| Rate of Correlation of DBS Lead Location to Long Term Outcomes | Rate of agreement between SIS-defined model of STN and actual DBS lead location and clinical motor outcomes | 3-6 months | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
STN, Parkinson's Disease, Subthalamic Nucleus
Postmarketing Safety Study of Q/LAIV in Subjects 2 Through 49 Years of Age

Study Overview
=================
Brief Summary
-----------------
This is an observational post-marketing study conducted in children and adults immunized with Q/LAIV as part of routine clinical practice at Kaiser Permanente Northern California (NCKP) sites.

Detailed Description
-----------------
Children and adults will be immunized with Q/LAIV as part of routine clinical practice at Kaiser Permanente Northern California (NCKP) sites. Using existing data on healthcare utilization, rates of medically attended events (MAEs) of interest will be evaluated in all eligible Q/LAIV recipients who are vaccinated in the Kaiser Permanente (KP) Northern California Health Care Plan during the 2013-2014 influenza season. Enrollment must include a minimum of 10,000 children 2 through 8 years of age; based on previous utilization of FluMist at NCKP, enrollment is expected to include approximately 80,000 children and adults 2 to 49 years of age.

Official Title
-----------------
Postmarketing Safety Study of Q/LAIV in Subjects 2 Through 49 Years of Age

Conditions
-----------------
Observation Safety

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: . Age 2 through 49 years at the time of vaccination (or index date for unvaccinated controls) . Membership in the KP Health Care Plan for at least 12 months prior to vaccination/index date . Continuous enrollment in KP Health Care Plan through 6 months following vaccination/index date. Exclusion Criteria: NONE
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Rates of medically attended events: hypersensitivity, seizures/convulsions | Rates of medically attended events from 0 to 3 days: hypersensitivity, seizures/convulsions | From 0-3 days | 
| Rates of medically attended events: lower respiratory tract infection, wheezing, Guillain-Barré syndrome, Bell's palsy, encephalitis, neuritis, vasculitis, any hospitalization and respiratory hospitalizations | Rates of medically attended events from 1 to 42 days: lower respiratory tract infection, wheezing, Guillain-Barré syndrome, Bell's palsy, encephalitis, neuritis, vasculitis, any hospitalization and respiratory hospitalizations | From 1 to 42 days | 
| Rates of medically attended events: narcolepsy/cataplexy | Rates of medically attended events from 1 to 180 days: narcolepsy/cataplexy | From 1 to 180 days | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
FluMist, Quadrivalent, Vaccine
Performance Evaluation Study for Clearblue Pregnancy Test

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to collect urine samples and dating scan information from women who wish to become pregnant. Urine samples will be tested in the laboratory with the Clearblue Pregnancy Test and the results correlated with volunteer information.

Detailed Description
-----------------
Approximately 800 female volunteers wishing to become pregnant will be recruited locally around 5 trial centers within the US. Daily urine samples and gestational age dating scan information obtained from the study will be used in laboratory tests to assess the accuracy of the Clearblue Pregnancy Test. Product assessment will involve testing of early morning urine samples collected by women during the cycle in which they conceived. Urine samples will be collected pre-conception to the end of the second trimester.

Official Title
-----------------
Performance Evaluation Study for Clearblue Pregnancy Test

Conditions
-----------------
Pregnancy

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Provide written informed consent to participate in the study and agree to comply with study procedures. Has menstrual bleeds. Seeking to become pregnant. Intend to seek medical care during pregnancy. Exclusion Criteria: Has positive pregnancy test on screening. Has received medical treatment for infertility or is participating in an assisted fertility program. Known condition to contra-indicate pregnancy.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 45 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| The agreement of the Clearblue Pregnancy Test result with Duration of Pregnancy. |  | 1 year | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Pregnancy test, Wishing to become pregnant